Publications

1. White KL, Vierkant RA, Fogarty ZC, Charbonneau B, Block MS, Pharoah PD, Chenevix-Trench G, for AOCS/ACS group;, Rossing MA, Cramer DW, Pearce CL, Schildkraut JM, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):987-92. Epub 2013 Mar 19. 2321911
   View PubMed
2. Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff BJ, Hamidi H, Shridhar V, Fan JB, Visscher DW, Olson JE, Hartmann LC, Bibikova M, Chien J, Cunningham Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet. 2013 Apr 16. [Epub ahead of print] 2315371
   View PubMed
3. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Ling Woo Y, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Palmieri Weber R, Vitonis AF, Vi Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications. 2013; 4:1628-. 2320508
   
4. Block MS, Suman VJ, Nevala WK, Kottschade LA, Creagan ET, Kaur JS, Quevedo JF, McWilliams RR, Markovic SN. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res. 2011 Oct; 21(5):438-45. 2172249
   View PubMed
5. Block MS, Nevala WK, Leontovich AA, Markovic SN. Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res. 2011 Apr 1; 17(7):1776-83. Epub 2011 Feb 24. 2151566
   View PubMed
6. Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8. 2163927
   View PubMed
7. Block MS, Markovic SN. The tumor/immune interface: Clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion. Am. J. Immunol. 2009; 5(1):29-49. 1978955
   View PubMed
8. Block MS, Vassallo R. Lack of FDG uptake in small cell carcinoma associated with ANNA-1 positive paraneoplastic autonomic neuropathy. J Thorac Oncol. 2008 May; 3(5):542-4. 1888392
   View PubMed
9. Block MS, Markovic SN. The clinical experience of cancer vaccines for malignant melanoma. G Ital Dermatol Venereol. 2007; 142(2):149-60. 1975782
   View PubMed
10. Johnson AJ, Mendez-Fernandez Y, Moyer AM, Sloma CR, Pirko I, Block MS, Rodriguez M, Pease LR. Antigen-specific CD8+ T cells mediate a peptide-induced fatal syndrome. J Immunol. 2005 Jun 1; 174(11):6854-62. 1720369
    View PubMed
11. Kennedy R, Undale AH, Kieper WC, Block MS, Pease LR, Celis E. Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses. J Immunol. 2005 Apr 1; 174(7):3967-77. 1705070
    View PubMed
12. Block MS, Mendez-Fernandez YV, Van Keulen VP, Hansen MJ, Allen KS, Taboas AL, Rodriguez M, Pease LR. Inability of bm14 mice to respond to Theiler's murine encephalomyelitis virus is caused by defective antigen presentation, not repertoire selection. J Immunol. 2005 Mar 1; 174(5):2756-62. 1694511
    View PubMed
13. Block MS, Hansen MJ, Van Keulen VP, Pease LR. MHC class I gene conversion mutations alter the CD8 T cell repertoire. J Immunol. 2003 Oct 15; 171(8):4006-10. 1417029
    View PubMed
14. Mendez-Fernandez YV, Pogulis RP, Block MS, Johnson AJ, Kuhns ST, Allen KS, Hansen MJ, Pease LR. Enhanced binding of low-affinity antibodies interacting simultaneously with targeted cell surface molecules and Fc receptor. Tissue Antigens. 2002 Dec; 60(6):515-25. 1318422
    View PubMed
15. Block MS, Johnson AJ, Mendez-Fernandez Y, Pease LR. Monomeric class I molecules mediate TCR/CD3 epsilon/CD8 interaction on the surface of T cells. J Immunol. 2001 Jul 15; 167(2):821-6. 1004162
    View PubMed
16. Lussow AR, Fanget L, Gao L, Block M, Buelow R, Pouletty P. Targeting of antihapten antibodies to activated T cells via an IL-2-hapten conjugate prolongs cardiac graft survival. Transplantation. 1996 Dec 27; 62(12):1703-8. 1887391
    View PubMed